TrialJournal of patient-reported outcomes2024

Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer.

Antoine Regnault et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.